Rr. Reeves et al., The effects of donepezil on the P300 auditory and visual cognitive evoked potentials of patients with Alzheimer's disease, AM J GER PS, 7(4), 1999, pp. 349-352
Donepezil is a cholinesterase inhibitor used for the treatment of patients
with mild to moderately severe Alzheimer's disease (AD). The purpose of thi
s study was to determine the effect of treatment with donepezil 5 mg qd on
cognitive evoked potentials (EPs) of patients with AD. Although treatment w
ith donepezil did not normalize EP latencies, treatment was associated with
a significant decrease in the auditory P300 latency (mean latency pretreat
ment = 401.5 msec; posttreatment = 392.7 msec.; P = 0.04), and the visual P
300 latency (mean latency pretreatment = 605.7 msec; posttreatment = 580.3
msec; P = 0.04). Treatment with donepezil had no discernible effect on audi
tory or visual P300 EP amplitudes.